Dmitry V. Isakov

Dmitry V. Isakov

Auto-generated profile, based on publicly available information

Dmitry V. Isakov

Institute of Experimental Medicine

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2021 in Medical Immunology (Russia)
Verified
Journal Article
Open access
PDF file
NLN. M. Lazareva
N. M. Lazareva
OBO. P. Baranova
O. P. Baranova
Igor KudryavtsevIgor Kudryavtsev
Igor Kudryavtsev
DID. V. Isakov
D. V. Isakov
NAN. A. Arsentieva
N. A. Arsentieva
ATA. A. Totolian
A. A. Totolian
Various immune cells as well as related cytokines are involved in immunopathogenesis of sarcoidosis and mechanisms of granuloma development. Currently, a role for chemokines in sarcoidosis has been extensively investigated, which is paralleled with a search for key molecules necessary for recruiting immune cells to intrusion site and granuloma formation as well as affecting outcome of the latter. Our study was aimed for determining level of plasma CCL17/TARC and CCL22/MDC chemokines in patients with sarcoidosis who received no immunosuppressive therapy is of high priority for clarifying some aspects in underlying immunopathogenesis as well as seeking out for secure clinical and laboratory criteria for assessing activity and disease prognosis. We studied peripheral blood plasma samples of the patients with sarcoidosis (n = 52). In 37% (19/52), they exhibited acute clinical manifestations, and 63% (33/52) had chronic sarcoidosis. The control group included peripheral blood samples from healthy volunteers (n = 22). The chemokine concentrations (pg/ml) were determined by multiplex analysis using xMAP technology (Luminex), and Milliplex MAP test system (Millipore, USA). In the patients with sarcoidosis, significantly higher levels of chemokines were shown relative to healthy volunteers: CCL17 – 78.24 pg/ml vs 26.24 pg/ml, p < 0.001; CCL22 – 660.60 pg/ml vs 405.00 pg/ml, p < 0.001. Evaluation of clinical and laboratory diagnostic characteristics for plasma chemokine levels in sarcoidosis patients allowed to assess their sensitivity and specificity. The respective values were as follows: in acute sarcoidosis: for CCL17 – 63% and 78%, CCL22 – 63% and 91%; in chronic sarcoidosis: CCL17 – 58% and 83%, CCL22 – 67% and 86%, respectively. In chronic sarcoidosis the levels of this chemokine correlated with the activity of angiotensin-converting enzyme (ACE), for CCL17 (r = 0.530; p = 0.003), for CCL22 (r = 0.446; p = 0.014). Patients with systemic lesions vs no systemic lesions (sarcoidosis of the respiratory system only) had significantly elevated CCL17 level: 102.82 pg/ml vs 32.72 pg/ml, p = 0.011. The concentration of chemokine CCL17 was significantly increased in patients with vs without signs of hepatomegaly: 130.73 pg/ml vs 51.60 pg/ml, p = 0.022. Levels of chemokines was significantly increased in patients with vs without ultrasound signs of splenomegaly comprising: for CCL17 – 249.18 pg/ml vs 46.87 pg/ml, p = 0.002; for CCL22 – 1271.40 pg/ml vs 660.63 pg/ml, p = 0.003. Thus, it should be noted that the peripheral blood plasma level of chemokines CCL17 and CCL22 may be used as additional prognostic markers in chronic sarcoidosis with varying scoring of clinical signs including with/without systemic disease manifestations.

1 January 2021 in Voprosy Ginekologii, Akušerstva i Perinatologii
Verified
Journal Article
Closed access
ADA.I. Davydov
A.I. Davydov
DID.V. Isakov
D.V. Isakov
RCR.а. Chilova
R.а. Chilova
VLV.A. Lebedev
V.A. Lebedev
MSM.N. Shakhlamova
M.N. Shakhlamova
A clinical and immunological analysis of the use of antiviral agent Inosine Pranobex (IP) as postoperative drug therapy in patients with cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) is performed. It is known that IP has a high anti-relapse activity adapted to the mechanisms of HPV elimination (through the sequence of oncoproteins E5, E6 and E7, a decrease in the synthesis of interferons (IFNs) occurs and resistance of HPV-infected cells to IFN is formed). In this work, a number of statements justifying the priority of IP in the treatment of patients with CIN associated with HPV is covered, namely that IP induces trained immunity, differentiation of the Th1 subset of CD4+ T cells and proliferation of CD8+ T cells. Conclusion. Inosine Pranobex should be considered as the medication of choice for postoperative monotherapy in patients with HPV-associated CIN. Inosine Pranobex is characterized by mechanisms of action in both virus-infected cells and through the activation of innate and adaptive immune cells. Key words: CIN, human papillomavirus, inosine pranobex, clinical and immunological aspects, trained immunity

1 January 2020 in Infekcionnye bolezni
Verified
Journal Article
Closed access
VIV.A. Isakov
V.A. Isakov
DID.V. Isakov
D.V. Isakov
NGN.A. Gavrish
N.A. Gavrish
YPYu.M. Paykacheva
Yu.M. Paykacheva

1 January 2019 in Voprosy Ginekologii, Akušerstva i Perinatologii
Verified
Journal Article
Closed access
VIV.A. Isakov
V.A. Isakov
DID.V. Isakov
D.V. Isakov
YPYu.M. Paykacheva
Yu.M. Paykacheva
LIL.G.Sokolov Clinical Hospital No 122 Centre For Herpesvirus Infections And Immunorehabilitation
L.G.Sokolov Clinical Hospital No 122 Centre For Herpesvirus Infections And Immunorehabilitation

1 January 2014 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
VIV. A. Isakov
V. A. Isakov
DID. V. Isakov
D. V. Isakov
При вирусных инфекциях дисбалансируются системы интерферонов, угнетаются клеточные и фагоцитарные реакции организма. Длительно персистирующие вирусные и бактериальные (микоплазмы, хламидии) инфекции влияют на развитие атопии и могут быть причиной обострений хронических заболеваний дыхательных путей. Показана высокая эффективность препарата Гроприносин (инозин пранобекс) в лечении и профилактике (иммунореабилитация) респираторных вирусных инфекций у часто болеющих взрослых и детей.

4 September 2024 in Cytokines and inflammation
Verified
Journal Article
Open access
PDF file
ASAndrei Savchenko
Andrei Savchenko
Igor KudryavtsevIgor Kudryavtsev
Igor Kudryavtsev
DIDmitry V. Isakov
Dmitry V. Isakov
ISIvan S. Sadowski
Ivan S. Sadowski
Vassiliy BelenyukVassiliy Belenyuk
Vassiliy Belenyuk
Vassiliy BelenyukVassiliy Belenyuk
Vassiliy Belenyuk
Post-COVID syndrome develops in 10–20% of people who have recovered from COVID-19 and it is characterized by impaired function of the nervous, cardiovascular, and immune systems. Previously, it was found that patients who recovered from infection with the SARS-CoV-2 virus had a decrease in the number and functional activity of NK cells. The aim of the study was to assess the effectiveness of recombinant human interleukin-2 administered to correct NK cell phenotype and functional activity in patients with post-COVID syndrome. Patients were examined after 3 months for acute COVID-19 of varying severity. The phenotype of the peripheral blood NK cells was studied by flow cytometry. It was found that disturbances in the cell subset composition in patients with post-COVID syndrome were characterized by low levels of mature (p=0.001) and cytotoxic NK cells (p=0.013), with increased release of immature NK cells (p=0.023). Functional deficiency of NK cells in post-COVID syndrome was characterized by lowered cytotoxic activity due to the decreased count of CD57+ (p=0.001) and CD8+ (p 0.001) NK cells. In the treatment of patients with post-COVID syndrome with recombinant human interleukin-2, peripheral blood NK cell count and functional potential were restored. In general, the effectiveness of using recombinant human interleukin in treatment of post-COVID syndrome has been proven in patients with low levels of NK cells. This article is a translation of the article by Savchenko AA, Kudryavtsev IV, Isakov DV, Sadowski IS, Belenyuk VD, Borisov AG. Recombinant Human Interleukin-2 Corrects NK Cell Phenotype and Functional Activity in Patients with Post-COVID Syndrome. Pharmaceuticals. 2023;16(4):537. DOI: 10.3390/ph16040537 Published with the permission of the copyright holder.